Anna A. Avagyan: Young Voices and Shared Purpose at EHA 2026
Anna A. Avagyan, Pediatric Hematologist/Oncologist at Pediatric Cancer and Blood Disorders Center of Armenia, shared a post on LinkedIn:
“We usually measure congresses by sessions, abstracts, and scientific updates.
But the real value is often harder to measure: a conversation after a talk, a colleague you meet by chance, a shared idea that suddenly feels possible.
EHA 2026 had all of this — strong science, meaningful connections, and many moments that reminded me why international communities matter.
As part of YoungEHA, I had the chance to connect with brilliant young specialists from many countries and, importantly, to bring a pediatric hematology perspective into the wider hematology community.
Armenia felt present too — in the discussions, in the network, and in the reminder that smaller countries can still have a strong professional voice.
Leaving EHA 2026 with a stronger feeling that our professional community is closer than it looks.”
Stay updated with Hemostasis Today.
-
Oct 13, 2026, 15:21Renel Tique: Advancing Hemophilia Care Through Global Collaboration and Clinical Innovation
-
Oct 13, 2026, 15:08Anastasia Chatzistamati: Unilateral Adrenal Haemorrhage in Primary Antiphospholipid Syndrome
-
Oct 13, 2026, 15:08Yousma Khan: Hematology Practical Series Day 11 Reticulocyte Count and Its Role in Anemia Diagnosis
-
Oct 13, 2026, 14:56Manal Rayyan: Multidisciplinary Collaboration in Rare Bleeding Disorders – Reflections from Abu Dhabi
-
Oct 13, 2026, 14:54Kalyan Roy: Understanding Blood Transfusion Sets for Safe Clinical Administration
-
Oct 13, 2026, 14:52Chedia Aroua: When Pharmacokinetics Meets Geophysics – Finding Unlikely Connections in Hemophilia Care
-
Oct 13, 2026, 14:47Mehmet Can Uğur: Honored by the Presence and Mentorship of Prof. Dargaud at Our Congress
-
Oct 13, 2026, 14:40Cheryl Loetscher: This Day in Drug Discovery – Wakix and H3 Receptor Inverse Agonism in Narcolepsy
-
Oct 13, 2026, 14:30Thirunavukkarasu Angappan: FVIII vs. FIX Expressive Durability – Key Lessons from GENEr8-1 and HOPE-B Long-Term Data